Literature DB >> 10742554

The role of complement anaphylatoxin C5a in neurodegeneration: implications in Alzheimer's disease.

P Mukherjee1, G M Pasinetti.   

Abstract

There is evidence that the complement system, a major component of inflammatory responses, may play an important role in neurodegenerative conditions such as Alzheimer's disease (AD). Work from our lab demonstrated that mice genetically deficient in the complement component C5 are more susceptible to hippocampal excitotoxic lesions (Pasinetti et al., 1996) and that the C5-derived ana;hylatoxin C5a may protect against excitotoxicity in vitro and in vivo (Osaka et al., 1999). Potential mechanisms identified in C5a-mediated neuroprotection include activation of mitogen activated protein (MAP)-kinase (Osaka et al., 1998; Osaka et al., 1999). This novel neuroprotective role of C5a complicates current theories that complement proteins augment beta-amyloid (Abeta) toxicity in AD. In view of the fact that the complement system represents a target for therapeutic interventions in AD, further characterization of the complex role of complement proteins is essential. Towards this aim, we have characterized a transgenic C5a receptor (C5aR) knockout (KO) mouse. Recent studies in the lab using C5aR-KO mice show that disruption of C5aR alters calcium calmodulin kinase (CaM-KII) signal transduction in brain cells. We are presently using C5aR-KO mice to study the role of C5a in caspase mediated apoptotic neuronal death. In this review we will attempt to delineate possible neuroprotective roles for C5a in mechanisms of neurotoxicity pertaining to AD.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10742554     DOI: 10.1016/s0165-5728(99)00261-1

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  25 in total

Review 1.  Complement in central nervous system inflammation.

Authors:  Scott R Barnum
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

Review 2.  Modern complement analysis.

Authors:  Michael Kirschfink; Tom E Mollnes
Journal:  Clin Diagn Lab Immunol       Date:  2003-11

Review 3.  Complement in neuroprotection and neurodegeneration.

Authors:  Vijay Yanamadala; Robert M Friedlander
Journal:  Trends Mol Med       Date:  2010-01-28       Impact factor: 11.951

Review 4.  The role of the anaphylatoxins in health and disease.

Authors:  Andreas Klos; Andrea J Tenner; Kay-Ole Johswich; Rahasson R Ager; Edimara S Reis; Jörg Köhl
Journal:  Mol Immunol       Date:  2009-05-28       Impact factor: 4.407

Review 5.  The complement cascade as a therapeutic target in intracerebral hemorrhage.

Authors:  Andrew F Ducruet; Brad E Zacharia; Zachary L Hickman; Bartosz T Grobelny; Mason L Yeh; Sergey A Sosunov; E Sander Connolly
Journal:  Exp Neurol       Date:  2009-07-24       Impact factor: 5.330

Review 6.  Neuroinflammation in Alzheimer's disease: chemokines produced by astrocytes and chemokine receptors.

Authors:  Chang Liu; Guohong Cui; Meiping Zhu; Xiangping Kang; Haidong Guo
Journal:  Int J Clin Exp Pathol       Date:  2014-12-01

7.  Complement C5 in experimental autoimmune encephalomyelitis (EAE) facilitates remyelination and prevents gliosis.

Authors:  Susanna H Weerth; Horea Rus; Moon L Shin; Cedric S Raine
Journal:  Am J Pathol       Date:  2003-09       Impact factor: 4.307

8.  Brain amyloid β protein and memory disruption in Alzheimer's disease.

Authors:  Weiming Xia
Journal:  Neuropsychiatr Dis Treat       Date:  2010-09-07       Impact factor: 2.570

9.  A novel role of complement in retinal degeneration.

Authors:  Minzhong Yu; Weilin Zou; Neal S Peachey; Thomas M McIntyre; Jinbo Liu
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-11-19       Impact factor: 4.799

10.  The C5a anaphylatoxin receptor CD88 is expressed in presynaptic terminals of hippocampal mossy fibres.

Authors:  James W Crane; Gilang P Baiquni; Robert Kp Sullivan; John D Lee; Pankaj Sah; Stephen M Taylor; Peter G Noakes; Trent M Woodruff
Journal:  J Neuroinflammation       Date:  2009-11-16       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.